Lexapro is a highly selective SSRI and is a derivative of Celexa. According to the research presented by the FDA, treatment with Lexapro is associated with significantly longer periods of remission between depressive episodes than treatment with Celexa.
Generalized Anxiety Disorder
In 2003, the FDA approved Lexapro for use in treating generalized anxiety disorder (GAD). Research showed that treatment which included the use of Lexapro proved to notably lessen the severity of GAD symptoms and frequency of occurrence.
Lexapro has proven to be safe for monitored use by patients aged 12 to 17 who have been diagnosed with major depressive disorder. Approved for use in this population in 2009, Lexapro is only the second antidepressant deemed to be safe in treating adolescents.
According to Forest Pharmaceuticals, improvement in indicated condition may be noted as early as one to four weeks after initiating treatment, with maximum benefits occurring within four to six weeks. In comparison, patients taking Celexa may not notice initial improvement until the fourth week of treatment.
Lexapro is generally prescribed as a once-daily medication. For those who have difficulty swallowing tablets, this medication is also available in liquid form.
In the fall of 2002, the U.S. Food and Drug Administration approved Lexapro for use in the treatment of major depressive disorder in adults. It is classified as a selective serotonin reuptake inhibitor (SSRI) antidepressant. The recommended initial prescribed daily dose is 10 mg and can be increased to 20 mg. Research conducted since its initial approval in 2002 has led to the expanded use of Lexapro in the management of other conditions and additional populations.